This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/2/2026
Welcome, ladies and gentlemen, to the third quarter 2026 earnings conference call for Tactile Medical. At this time, all participants have been placed in a listen-only mode. At the end of the company's prepared remarks, we will conduct a question and answer session. Please note that this conference call is being recorded and will be available on the company's website for replay shortly. I would now like to turn the call over to Sam Bensinger, Investor Relations at Gilmartin Group for a few introductory comments. Please go ahead.
Good afternoon, and thank you for joining today's call. With me from Tactile Medical's management team are Sheri Dodd, Chief Executive Officer, and Elaine Birkemeyer, Chief Financial Officer. Before we begin, I'd like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties. These could cause actual results to differ materially from those indicated, including those identified in the risk factor section of our annual report on Form 10-K, as well as our most recent 10-Q filing to be filed with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the investor relations portion of our website. With that, I'll now turn the call over to Sheri.
Thanks, Sam. Good afternoon, everyone, and welcome to our third quarter 2026 earnings call. Here with me is Elaine Birkemeyer, our Chief Financial Officer. We delivered total revenue of $91.9 million in Q3, led by a 13% year-over-year growth in lymphedema, marking our fifth consecutive quarter of above-market double-digit growth. This consistency demonstrates the durability of our leadership position and the substantial runway created by a market that remains significantly underpenetrated. Airway clearance revenue was $10 million, down year-over-year as anticipated due to the one-time DME inventory transition associated with the launch of our next-generation AfloVest system. The same DME customers we highlighted in Q2 continued to work through temporary excess inventory during Q3. There were no material changes in the underlying dynamics of the business, and we continue to expect airway clearance revenue to improve sequentially in the fourth quarter. Across the portfolio, we continue to balance strong growth in our core lymphedema business with disciplined execution. Gross margin expanded 90 basis points year-over-year in Q3 to 76.7%, contributing to adjusted EBITDA of $14.3 million. This marked 12th consecutive quarter of year-over-year gross margin expansion. Importantly, we have achieved this sustained improvement while continuing to invest in our product offerings to deliver greater value to patients and providers. Based on our year-to-date performance and our expectations for the fourth quarter, we are maintaining our full-year 2026 revenue guidance of $360 to $366 million and raising our adjusted EBITDA guidance Thank you for joining us. I'll now turn a closer review of our lymphedema business line, including Q3 performance and recent progress against our three strategic priorities. Elaine will then review our financial results and the outlook for the remainder of the year. Lymphedema remains our core business and primary growth. Our Q3 results demonstrate our market leadership in both basic and advanced pneumatic compression devices, with revenue growing 13% year-over-year to $81.8 million. Sequentially, lymphedema revenue grew 11%, supported by a recovery from the Medicare ordering timing disruption associated with the April implementation of prior authorization requirements. As expected, the prior authorization process has stabilized, as our teams and the MACs have gained experience with the new requirements, and we believe this timing disruption is now behind us. Medicare revenue returned to growth in Q3, up 11% year over year. Beyond Medicare stabilization, the quarter's performance was driven by execution across several key drivers. Our go-to-market investments in sales reps and CRM technology are extending the reach and impact of our commercial organization. Clinic visits increased 19% year-over-year in the third quarter, and referring clinics grew more than 10% year-to-date. These results are enabled by enhanced market insights, that help our teams identify and prioritize referral opportunities across our account base. Our clinician focused marketing programs are also delivering measurable returns with select events generating 20 to 45% order growth from participating accounts in the 90 days following the event compared to the 90 days prior. And through our medical education team, we have educated more than 13,000 clinicians who treat lymphedema patients so far in 2026, already 25% more than in all of 2025. This expands the number of providers equipped to identify patients and refer them to appropriate therapy. Additionally, broader patient access to advanced pumps remains durable following our tighter alignment with the NCD policy, and this is reflected in our product mix. As part of the next phase of our go-to-market playbook, this quarter we established a dedicated strategic accounts team within our broader commercial organization. This team will focus on deepening engagement with larger health systems and IDNs while expanding referral opportunities within existing high-volume regional and national accounts. Taken together, these trends give us confidence in our ability to deliver sequential lymphedema growth in Q4. We are beginning to see benefits from investments in our operating model and order process, which are improving efficiency and service quality as patients move from referral to therapy. The strong prior year comparison next quarter resulting from the initial benefit of our alignment with the NCD will moderate year-over-year growth but does not change our confidence in the underlying momentum of the business. Looking beyond our third quarter results, we are executing well on our three strategic priorities designed to sustain double-digit growth, expanding access to care, creating value across the patient journey, and expanding treatment options. Together, these priorities form a compelling growth model, As with most market development opportunities, growth starts with diagnosis. Patients must first be identified, diagnosed, and referred before we can help them access clinically appropriate therapy. Expanding access to care means helping more patients get diagnosed and referred into the care pathway. But a referral is only the beginning of the order process. and growth also requires pulling a higher percentage of referrals through to shipment. Today, not every diagnosed patient with lymphedema makes it through the documentation and order process necessary to receive therapy. And each patient lost along the way is a diagnosed patient who potentially goes underserved. Creating value across the patient journey is about closing the gap and converting more eligible referrals to shipments, which is where we serve the patient and how we generate revenue. And expanding treatment options supports every step of that pathway. A broader portfolio gives clinicians more solutions for their patients, supports more additional referral opportunities, and extends the patient populations and disease stages we can serve. As these capabilities scale, we also expect greater productivity and operating leverage to support adjusted EBITDA growth over time. Put simply, sustained growth in our lymphedema business is not solely a function of adding sales representatives. It comes from helping more patients get diagnosed and referred, supporting more of those referrals so they can reach therapy, and expanding the range of patients and therapy needs we can address. Our first priority is expanding access to care through earlier diagnosis and broader patient coverage. The opportunity is significant. An estimated 20 million people in the U.S. are living with undiagnosed lymphedema, and many diagnosed patients continue to face coverage barriers. Our Lymphotec 3D scanner currently gives clinicians an FDA-cleared, quantitative way to measure limb volume and circumference. supporting earlier and more consistent identification of the disease. We are encouraged that Lymphatec is currently in use and generating revenue at leading academic medical centers, even ahead of an established reimbursement pathway, demonstrating its utility in clinical practice. We recently achieved an important regulatory milestone, receiving FDA 510 clearance for an expanded indication of the Lymphatec 3D scanner. Lymphatec is now cleared to provide circumference and volume measurements to aid in the assessment of lymphedema. This expands Lymphatec's clinical positioning beyond measurement and surveillance alone, and this expanded indication strengthens the foundation for our broader diagnostic strategy, including our work on clinical adoption, reimbursement, and further integrated diagnostics. On Lymphatec 3D scanner reimbursement, AHRQ application for a Category 3 CPT Thank you for joining us. We are also making progress in broadening payer access for patients who already have been diagnosed with lymphedema. Following publication of the six-month results from our randomized control trial of FlexiTouch therapy for head and neck cancer-related lymphedema, we have begun to see movement among commercial payers, with a small number removing restrictive experimental and investigational designation from their policies. Significant work remains, but these early policy changes demonstrate that our clinical evidence and payer engagement can expand coverage over time, opening access to therapy for more eligible patients and supporting additional referral opportunities. Our second priority is creating value across the patient journey. While we see opportunities to improve the experience at every stage of care, our current focus is on the highest impact stage of the journey. Helping more eligible patients successfully start therapy. By reducing friction in the upfront documentation and order process, we can improve conversion from referral to shipment and ensure more patients receive the therapy prescribed by their clinician. This benefits patients, simplifies the experience for referring clinicians and their staff, and supports a more efficient and stable operating model. Ultimately, increasing access to therapy is a key driver of both patient value and sustainable growth. During the quarter, we made organizational and operating model changes to strengthen how orders move from referral to shipment. We also continue to replatform our end-to-end order process through our AI-enabled order management platform and care navigation work. Together, these efforts are designed to reduce friction, improve visibility into patient progression, and strengthen execution across the referral to shipment process. We are already seeing tangible results in medical record review, one step within the broader order process, where technology-enabled improvements have reduced average review time by approximately 50%. While meaningful work remains, this early result demonstrates the potential to improve service levels, Thank you for joining us. In this newly created role, Steve will lead our order operations and patient services teams, connecting capabilities that support a patient from referral through shipment into one operating organization. This structure will enable more coordinated decision-making across the full journey and help us extend process improvements more broadly, creating a better experience, greater capacity, and a more scalable operating model. Steve brings breadth and depth of experience in revenue cycle management, field-based patient educators, call center, and DME operations. This is the right time to bring an executive level enterprise operations leader to our team, and we are excited to have him on board. Our third priority is expanding treatment options. A broader innovation portfolio allows us to address more patient needs, support additional referral opportunities, and serve patients across a broader range of disease stages. We are advancing opportunities that complement our core pneumatic compression therapies and expand the patient populations we can address. Consistent with our previously stated commitment, a significant milestone came in October when we filed a 510K application for FlexiTouch Pro, a meaningful enhancement to our advanced pneumatic compression system. FlexiTouch Pro is designed to improve the patient and clinician experience through usability and connectivity enhancements, that simplify therapy administration while delivering the clinical effectiveness that has made FlexiTouch the long-standing market leader. Subject to completion of the regulatory process, we are targeting a commercial launch of FlexiTouch Pro in the second half of 2027. This innovation is intended to reinforce our leadership in advanced pneumatic compression and increase the value we deliver through our core franchise. We are also preparing to introduce Myosleeve in the U.S. through our partnership with Elastomed. Our next milestone is a focused VA pilot beginning in late Q4, which will help us evaluate the patient experience, clinical fit, and appropriate go-to-market model before broader commercialization. Myosleeve is not reflected in our 2026 guidance, and we expect its contribution to build gradually over time. strategically, it represents an opportunity to serve additional patients and expand the range of therapy needs our portfolio can address. Overall, we remain confident in the durability of our lymphedema business and the opportunities ahead in 2027 and beyond. Each of our strategic priorities is at a different stage of development, and their impact will build over time. Collectively, they are designed to strengthen the fundamental drivers of our lymphedema business. More patients being identified and referred, More eligible patients receiving therapy, and a broader range of patients and care needs we can serve. That is the growth model we believe can support durable revenue growth and improving profitability over time. With that, I'll turn the call over to Elaine to review our financial results and full year outlook.
You're reading a preview of the TCMD Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing